Top in ID: Johnson & Johnson vaccine; ‘substantial’ prevalence of long COVID

The FDA has restricted the use of Johnson & Johnson’s COVID-19 vaccine due to its association with thrombosis with thrombocytopenia syndrome.
The vaccine will be available to adults who do not have access to other COVID-19 vaccines and those who elect to only receive the Johnson & Johnson vaccine and would otherwise be unvaccinated, according to the FDA. It was the top story in infectious disease last week.
The second top story was about long COVID and new data that show more than 200 million people globally are suffering from COVID-19’s long-term effects.
Read the top

The FDA has restricted the use of Johnson & Johnson’s COVID-19 vaccine due to its association with thrombosis with thrombocytopenia syndrome.
The vaccine will be available to adults who do not have access to other COVID-19 vaccines and those who elect to only receive the Johnson & Johnson vaccine and would otherwise be unvaccinated, according to the FDA. It was the top story in infectious disease last week.
The second top story was about long COVID and new data that show more than 200 million people globally are suffering from COVID-19’s long-term effects.
Read the top